01 1Cipla
01 1FLUTICASONE PROPIONATE USP (PROCESS III)
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2019-01-08
Pay. Date : 2018-11-27
DMF Number : 33172
Submission : 2018-11-05
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is FLUTICASONE PROPIONATE USP (PROCESS III), with a corresponding US DMF Number 33172.
Remarkably, this DMF maintains an Active status since its submission on November 05, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 08, 2019, and payment made on November 27, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II
